ReviewMolecular medicine reports2026
Role of CMTM6 in disease pathogenesis and clinical translation potential (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine‑like factor (CKLF)‑like MARVEL transmembrane domain‑containing (CMTM) family belongs to the human CKLF gene superfamily, which comprises CKLF and CMTM1‑8. Among its members, CMTM6 encodes a protein exhibiting structural and functional characteristics that lie between classical chemokines and tetraspanins. CMTM6 is expressed in several normal tissues, including those of the immune, reproductive and nervous systems. Notably, its expression is frequently upregulated across a broad spectrum of tumors including, but not limited to, carcinomas of the lung, liver and gastrointestinal tract. CMTM6 contributes to tumor proliferation, invasion and metastasis by inhibiting immune responses, facilitating immune evasion and inducing epithelial‑mesenchymal transition, thereby influencing patient prognosis and survival outcomes. The present review systematically summarizes the molecular functions, mechanisms of action, disease‑related expression patterns and clinical translational applications of CMTM6, aiming to provide novel clinical insights and to guide the development of CMTM6‑targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.